Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.33 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632524 | 0.78 | PDE3B (0.47) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL18663957 | 0.75 | PDE1A (0.40) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL11088652 | 0.72 | CHEK1 (0.49) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL13114978 | 0.71 | NOTUM (0.43) | CHEK1GRM2NOTUM | |
| SCHEMBL17403218 | 0.68 | CHEK1 (0.42) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL20996080 | 0.68 | CHEK1 (0.39) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL19646489 | 0.68 | CHEK1 (0.42) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL21034104 | 0.64 | CHEK1 (0.35) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL560634 | 0.63 | MAPT (0.54) | CHEK1PDE3BPDE3APDE1APDE1B | |
| SCHEMBL1991156 | 0.63 | CHEK1 (0.40) | CHEK1PDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| WO-2017046318-A1 | TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | OAT, XDH, MAPT | CHEK1 1722/4885PDE3B 1028/4885PDE3A 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.